The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

November 1, 2024

Study Completion Date

March 1, 2025

Conditions
Obesity
Interventions
DEVICE

AGBS

The AGBS is designed to promote weight loss in individuals with obesity. The AGBS includes the Allurion Balloon, which is a temporary gastric balloon that promotes weight loss in individuals with obesity. The AGBS consists of up to 2 balloons placed during a 1-year period.

Trial Locations (17)

11004

Northwell Health, New Hyde Park

15213

University of Pittsburg Medical Center, Pittsburgh

28204

Atrium Health Care, Charlotte

33166

University of Miami, Miller School of Medicine, Doral

37204

Vanderbilt Center for Surgical Weight Loss, Nashville

46202

Indiana University, Indianapolis

60657

Chicago Institue of Advanced Surgery, Chicago

63110

Washington University, St Louis

64111

Saint Luke's Hospital Kansas City, Kansas City

68106

University of Nebraska Medical Center, Omaha

77401

UT Health Science Center at Houston, Bellaire

78258

Segar MD, San Antonio

80045

University of Colorado, Anschutz Health and Wellness Center, Aurora

85258

HonorHealth Research Institute, Scottsdale

90048

Cedars-Sinai, Los Angeles

02111

Tufts Medical Center, Boston

01805

Lahey Hospital and Medical Center, Burlington

Sponsors
All Listed Sponsors
lead

Allurion Technologies

INDUSTRY

NCT05368259 - The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY) | Biotech Hunter | Biotech Hunter